73303-88-5

Basic information

• Product Name: 2-Mercapto-2,2-diMethylethanol
• Synonyms: 2-Mercapto-2,2-diMethylethanol;2-methyl-1-hydroxypropane-2-thiol;2-methyl-2-sulfanylpropan-1-ol
• CAS NO: 73303-88-5
• Molecular Formula: C₄H₁₀OS
• Molecular Weight: 106.1866
• Mol File: 73303-88-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Storage Temp.: -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform, Methanol
• CAS DataBase Reference: 2-Mercapto-2,2-diMethylethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Mercapto-2,2-diMethylethanol(73303-88-5)
• EPA Substance Registry System: 2-Mercapto-2,2-diMethylethanol(73303-88-5)

Safety Data

• Hazardous Substances Data: 73303-88-5(Hazardous Substances Data)

Usage

Description

2-Mercapto-2,2-dimethylethanol, a derivative of 2-Mercaptoethanol (M225480), is a versatile synthetic intermediate with significant applications in various fields. It is characterized by its unique chemical structure, which allows it to form covalent bonds with a wide range of molecules, making it a valuable compound for research and development.

Uses

Used in Pharmaceutical Industry:
2-Mercapto-2,2-dimethylethanol is used as a synthetic intermediate for the development of novel pharmaceutical compounds. Its ability to form covalent bonds with other molecules makes it a promising candidate for the creation of new drugs with improved efficacy and selectivity.
Used in Nanotechnology:
2-Mercapto-2,2-dimethylethanol is used as a key component in the synthesis of nano-graphene, a material with potential applications in cellular imaging and drug delivery. Its unique properties enable the creation of nanostructures with enhanced functionality and biocompatibility.
Used in Polymer Science:
2-Mercapto-2,2-dimethylethanol is used as a building block in the synthesis of multifunctional polymeric micelles, which are employed in the specific targeting of tumor disruption. These micelles can be designed to selectively target cancer cells, improving the effectiveness of cancer treatments and reducing side effects.

Upstream product

• 412275-21-9 1-acetoxy-2-acetylsulfanyl-2-methyl-propane 
• 73303-72-7 trimethylsilyl 2-(methoxycarbonyl)-2-propanesulfinate 
• 132182-01-5 2,2'-dithiobis(2-mercapto-2-methylpropan-1-ol) 
• 15581-80-3 2,2'-dithiobis(2-methylpropanal) 
• 1151713-51-7 2-acetylsulfanyl-2-methylpropionic acid ethyl ester 

Downstream Products

• 74195-16-7 4,4-Dimethyl-2-n-hexyl-1,3-oxathiolane 
• 94618-47-0 4,4-Dimethyl-2-(tetrahydro-furan-2-yl)-[1,3]oxathiolane 
• 149083-30-7 4,4-Dimethyl-2-non-8-en-3-ynyl-[1,3]oxathiolane 
• 73675-89-5 4,4-Dimethyl-1,3-dioxathiolane 
• 74195-27-0 6,6-Dimethyl-1,3-dioxa-5-thiacycloheptane 
• 291518-72-4 2-methyl-1-hydroxypropane-2-nitrosothiol 
• 865469-09-6 C₉H₁₈O₂S 

Relevant articles and documents

Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity

The ability to selectively degrade proteins with bifunctional small molecules has the potential to fundamentally alter therapy in a variety of diseases. However, the relatively large size of these chimeric molecules often results in challenging physico-chemical properties (e. g., low aqueous solubility) and poor pharmacokinetics which may complicate their in vivo applications. We recently discovered an exquisitely potent chimeric BET degrader (GNE-987) which exhibited picomolar cell potencies but also demonstrated low in vivo exposures. In an effort to improve the pharmacokinetic properties of this molecule, we discovered the first degrader-antibody conjugate by attaching GNE-987 to an anti-CLL1 antibody via a novel linker. A single IV dose of the conjugate afforded sustained in vivo exposures that resulted in antigen-specific tumor regressions. Enhancement of a chimeric protein degrader with poor in vivo properties through antibody conjugation thereby expands the utility of directed protein degradation as both a biological tool and a therapeutic possibility.

HINDERED DISULFIDE DRUG CONJUGATES

The invention relates generally to disulfide drug conjugates wherein a linker comprising a sulfur-bearing carbon atom substituted with at least one hydrocarbyl or substituted hydrocarbyl is conjugated by a disulfide bond to a cysteine sulfur atom of a targeting carrier, and wherein the linker is further conjugated to a drug moiety. The invention further relates to activated linker-drug conjugates suitable for conjugation to a targeting carrier by a disulfide bond. The invention further relates to methods for preparing hindered disulfide drug conjugates.

Nitrostated and nitrosylated prostaglandins, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.